Several clinical trials suggested that PD-1/PD-L1 inhibitor plus chemotherapy and/or antiangiogenic therapy could dramatically prolong both PFS and OS in patients with NSCLC [13–15]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.